


Enterprise Solutions: Effective Corrective Action and Prevention Plans (CAPA) Following Internal Audits of Clinical Research Trials

UT Southwestern Medical Center
Office of Compliance


Deepika Bhatia, MSBME, CCRP, CHRC
Assistant Director, Research and Academics

Trissi Gray, MBA, CHRC
Assistant Director, Health System Affairs

Session Objectives




MEDICAL CENTER MEDICAL



PROFILE PROFILE PROFILE


Research Footprint



Home to many nationally and
internationally recognized
physicians and scientists.

- 6 Nobel Laureates
- 23 National Academy of Sciences members
- 19 National Academy of Medicine members

Research Footprint




5

Polling Question: What is your role in your Research Compliance Program?

- A. Compliance Officer
- B. Legal Counsel
- C. Compliance Administrator/Specialist
- D. Billing Compliance
- E. Other


6

Research Compliance Offices




7

Research Systems & Tools



8


Office of Compliance Reporting Structure



Office of Compliance Org Chart
FY16 FTE = 22

9

Human Subject Research Oversight




10

Polling Question: How is Your Research Compliance Program Structured?

Where does your program currently reside:

- A. Office of Compliance
- B. Internal Audit
- C. Research Administration
- D. The Medical School
- E. Other



11

Research Compliance Activities


Office of Compliance

- **Quarterly QA review of full board, approved, IIS**
- Conflicts of Interest
- Fiscal Management – Cost transfer, effort reporting transition
- **Quarterly clinical research billing compliance review**
- Export Control Analyses & Screenings

12


Research Compliance Activities – Monitoring

Research Operations




13

Three Lines of Defense



14


Optimizing Resources: Program Maturity



15

Polling Question: How Mature is Your Research Compliance Program?

- A. <5 years
- B. 5-10 years
- C. 10+ years
- D. Don't know




16

Annual Risk Assessments

FF17 Proposed Work Plan Activities

FF 2017 Planned Risk Mitigation Activities by Estimated Time



Risk Category	
A	Establishment of research and clinical research with the
B	Translational research activities
C	Translational research activities and clinical research
D	Translational research activities and clinical research
E	Translational research activities and clinical research
F	Translational research activities and clinical research
G	Translational research activities and clinical research
H	Translational research activities and clinical research
I	Translational research activities and clinical research
J	Translational research activities and clinical research
K	Translational research activities and clinical research
L	Translational research activities and clinical research
M	Translational research activities and clinical research
N	Translational research activities and clinical research
O	Translational research activities and clinical research
P	Translational research activities and clinical research
Q	Translational research activities and clinical research
R	Translational research activities and clinical research
S	Translational research activities and clinical research
T	Translational research activities and clinical research
U	Translational research activities and clinical research
V	Translational research activities and clinical research
W	Translational research activities and clinical research
X	Translational research activities and clinical research
Y	Translational research activities and clinical research
Z	Translational research activities and clinical research



Work Plan			
Goal / Objective	Target Completion	Progress	Notes
Develop a comprehensive annual compliance awareness campaign and rollout as planned	Ongoing	Education & Training	All monthly awareness events and activities are conducted as indicated in the campaign plan.
Develop update experimental specific policy and procedure inventory to demonstrate continued adherence to the elements of an effective compliance program	Ongoing	Review, Standard	Adequate FIPs are in place and up-to-date or in development to maintain stated adherence.
Conduct a baseline regulatory compliance risk assessments of select critical areas.	Q1	Auditing & Monitoring	Field work is completed. Report of findings is developed and published to stakeholders.
Perform semi-annual human subjects research review.	Q1	Auditing & Monitoring	Field work is completed. Report of findings is developed and published to stakeholders.
Monitoring program for use of PHI in research is developed and implemented.	Q1	Auditing & Monitoring	Surveillance methodology is developed, and reviews are completed and documented. Findings observations are reviewed with stakeholders with appropriate reporting to oversight committees.
Monitoring program for use of PHI in billing departments is developed and implemented.	Q1	Auditing & Monitoring	Surveillance methodology is developed, and reviews are completed and documented. Findings observations are reviewed with stakeholders with appropriate reporting to oversight committees.
Conduct an inspection of research facilities in collaboration with HHS.	Q2	Auditing & Monitoring	Inspection report is developed. Findings and observations are reviewed with stakeholders.
Conclude risk mitigation analysis re: identify theft medical identity theft and develop agreed upon tools and mitigation strategies.	Q2	Auditing & Monitoring	Stakeholder agreement reached on best methods to balance risk and available resources. Complete all agreed upon action items.
Enhance electronic surveillance to monitor for inappropriate access of electronic medical records.	Q2	Auditing & Monitoring	Develop and implement at least 2 new surveillance reports and complete quarterly review and follow up. (e.g., same address, same name, same department, access and/or high volume of record access)
Facilitate semi-annual self reviews for non-clinical areas that use PHI.	Q2	Auditing & Monitoring	Results are evaluated, corrective action plans are created, and implementation of same is monitored.
Conduct a compliance-related operational review to ensure adherence with Health System and	Q2	Auditing & Monitoring	Field work is completed. Report of findings is developed and published to stakeholders.

17

Compliance: Auditing and Monitoring


Element of an effective compliance program is to conduct periodic auditing and monitoring of the organization's adherence with regulatory guidance and established written standards.

Audit and Review Types:

Baseline/Probe	• High level review to determine whether a compliance issue exists
Routine	• Evaluate ongoing compliance adherence
Follow-up	• Enlarge sample based on error rates identified during a routine audit
Requested	• Requested review by Leadership and/or Clinical Department
Focused	• For cause review

18

AUDIT PROCESS



19

Auditing and Monitoring: Compliance Risk Areas

Risk Level	Examples of Study Types
High (Full Board)	IND/IDE, Phase 1, UTSW Lead Coordinating Site, Investigator-Initiated
Moderate (Full Board)	Phase 2, Phase 3, Pediatrics
Low (Expedited, Exempt, or Registration)	Prospective or retrospective data and/or specimen collection, including interventional and/or treatment studies, repository or registry studies
Lowest (Studies Already Monitored)	High, moderate, or low risk studies monitored by external sponsors/CROs or internal groups, e.g. SCCC CRO or Office of Research Protections



*Categories

1. Eligibility
2. Informed Consent Process and Documentation
3. Essential Documentation filed in Regulatory Binder
4. Investigational Product - Management & Accountability
5. CRF and Source Verification
6. Protocol Compliance
7. Safety Monitoring - Adverse Events & Data
8. Privacy and Deidentification of Data
9. Appropriate Record Storage and Retention
10. Recruitment Strategies
11. Study Population
12. Sponsor Monitoring

20

Monitoring: Exceptions and Ratings


Major Exception - Generally 1) significantly compromises the integrity of the study or the safety of the subject, 2) violates or significantly deviates from Federal or UTSW requirements or policies or 3) represents cumulative minor deficiencies of the same nature.

Minor Exception - Occurs when the protocol is not followed exactly, but the data remain usable and valid or is a less serious deviation from Federal regulations or UTSW policies.

Exceeds Expectation	<ul style="list-style-type: none"> • <5 minor deficiencies noted
Meets Expectation	<ul style="list-style-type: none"> • <5 major deficiencies noted
Does Not Meet Expectation	<p>If any of the following is noted:</p> <ul style="list-style-type: none"> • 5 or more major deficiencies noted per subject chart reviewed • Single life-threatening major deficiency • Concern for misconduct or fraud

21

QA Process



22

CAPA Planning

- Debrief
- Study Team
- Operational Stakeholders
 - HRPP
 - CRS
 - Other Departments



25

Reporting Serious/Continuing Non-Compliance



26

Elements Of CAPA Plan

1. Specific areas requiring compliance attention;
2. Additional training requirements;
3. Ceasing problematic process;
4. Change in procedures;
5. Repaying overpayments;
6. Reporting to the appropriate governmental authorities;
7. Further review and/or investigation;
8. Determining whether the problem is systematic;
9. Disciplinary action; and
10. Notice to journals, publishers, or other media services concerning issues of research integrity.

27

Recurring Exceptions

- Informed Consent Template & Process
- Data Mgmt – Sharing & Disclosures
- Claim Direction – RSH vs SOC
- Coverage Analysis & Protocol
- Clinical Research Documentation
 - Source Docs
 - Epic
- Study Set Up – Double Blinded Protocols



28


Organizational Engagement: Advocating Change

21
29

Rules of Engagement: Executive Trust

- Finding ways to connect with President, EVP, VPRA
 - Tone at the Top: Culture of Compliance
 - Executive Leadership Team- Dedicated Quarterly Meetings for Compliance
 - Meaningful Data: Compliance Dashboards, Real-time Auditing and Monitoring
 - Study Team and Principal Investigator Rounding and Town Hall Meetings

- Compliance - Valued Addition to Operations
 - Research Administration and Services
 - Sponsored Program Administration
 - Health System Affairs- University Hospital and Ambulatory Services




30

Compliance: The Change Agent



31

Understanding the Marriage: Operations vs. Compliance



**Risk
Mitigation**



32

Compliance Program: Mission, Vision and Value

Each day our patients, students, and the public count on us to deliver the very best in patient care, state-of-the-art research, and outstanding medical education. As a University, we strive to meet and exceed these goals. By fostering a culture of compliance with established policies and standards, we reassure the community of our commitment to adhering to all applicable laws, rules, and policies.

Daniel K. Podolsky, M.D.
President, UT Southwestern Medical Center

Source: UT Southwestern Medical Center, Standards of Conduct (2013)

33



Contact Information:

Deepika Bhatia, MSBME,CCRP, CHRC, Assistant Director, Research and Academic Compliance
deepika.bhatia@utsouthwestern.edu

Trissi Gray, MBA, CHRC, Assistant Director, Health System Compliance
trissi.gray@utsouthwestern.edu